Not currently recruiting at UCSF
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Summary
- Eligibility
- for people ages 12-17 (full criteria)
- Location
- at San Francisco 5391959, California 5332921 and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Othman Aljohani
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Othman Aljohani
Dr. Othman A. Aljohani is a pediatric cardiologist who cares for children with complex heart conditions that they were born with or developed during childhood. He serves as medical director of the programs for pediatric heart transplantation and mechanical circulatory support.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Cytokinetics
- ID
- NCT06412666
- Phase
- Phase 2/3 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 40 study participants
- Last Updated